DOCSLIB.ORG

Angiotensin-Converting Enzyme (ACE) Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS Dana Bartlett, RN, BSN, MSN, MA, CSPI Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevier, Lippincott, and Thieme. He has written widely on the subject of toxicology and was a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Rocky Mountain Poison Control Center. ABSTRACT The class of angiotensin converting enzyme (ACE) inhibitors are widely prescribed for conditions of primary hypertension. Hypertension is a very common disease that affects approximately 75 million Americans or roughly 1 in 3 adults. ACE inhibitors also have distinct, specific advantages for treating hypertensive patients who have chronic kidney disease, diabetes mellitus, heart failure, and myocardial infarction. They are known to prevent mortality related to a cardiovascular event. Except for captopril and lisinopril, the ACE inhibitors are pro-drugs, changed in the liver to a pharmacologically active metabolite. ACE inhibitors may differ in their pharmacokinetic properties, such as peak blood levels and effect on blood pressure depending on the drug. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities. Continuing Education Credit Designation This educational activity is credited for 2.5 hours. Nurses may only claim credit commensurate with the credit awarded for completion of this course activity. Pharmacology content is 2.5 hours. Statement of Learning Need It is important for health clinicians to have current information about ACE inhibitors, specifically, the pharmacological profile, therapeutic uses, adverse effects, contraindications, warnings, and for the treatment of certain disease states. Additionally, patient monitoring during therapy with an ACE inhibitor, and how to manage ACE inhibitor-induced angioedema and ACE inhibitor overdose will impact patient care outcomes. Course Purpose To increase health clinician knowledge of the recommended use, benefits and risks of ACE Inhibitor medication use. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 2 Target Audience Advanced Practice Registered Nurses and Registered Nurses (Interdisciplinary Health Team Members, including Vocational Nurses and Medical Assistants may obtain a Certificate of Completion) Course Author & Planning Team Conflict of Interest Disclosures Dana Bartlett, RN, BSN, MSN, MA, CSPI, William S. Cook, PhD, Douglas Lawrence, MA, Susan DePasquale, MSN, FPMHNP-BC All have no disclosures Acknowledgement of Commercial Support There is no commercial support for this course. Please take time to complete a self-assessment of knowledge, on page 4, sample questions before reading the article. Opportunity to complete a self-assessment of knowledge learned will be provided at the end of the course. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 3 1. The renin-angiotensin system (RAS) regulates blood pressure by, among other things, a. causing the kidneys to convert pre-renin to renin. b. synthesizing renin to angiotensin I in the kidneys. c. increasing renal blood flow. d. increasing serum sodium. 2. _______________ binds to specific receptors, and it increases blood pressure by its action as a potent vasoconstrictor. a. Angiotensin I b. Renin c. Angiotensin II d. Sodium 3. The angiotensin converting enzyme (ACE) inhibitors have the net effect of a. decreasing the activity of renin. b. lowering blood pressure. c. increasing the vasoconstrictive action of angiotensin II. d. increasing serum sodium levels in the body. 4. True or False: The ACE inhibitors and the angiotensin receptors blockers (ARBs) both lower blood pressure by their effects on the RAS using the same methods. a. True b. False 5. Treatment of __________________ is a primary use of ACE inhibitors. a. hypotension b. aortic stenosis c. cholestatic jaundice d. cardiovascular diseases nursece4less.com nursece4less.com nursece4less.com nursece4less.com 4 Introduction The angiotensin converting enzyme inhibitors are one of the most widely used antihypertensive medications, and they are a first-line choice for treating primary hypertension according to the Eighth Joint National Committee guideline for the management of high blood pressure in the general non-black population and in patients 18 years or older who have chronic kidney disease. The angiotensin converting enzyme inhibitors are also often used to treat hypertension associated with specific clinical conditions, diabetic nephropathy, and their use is considered standard care for patients who have recently had an ST segment elevation myocardial infarction. ACE Inhibitors And The Renin-Angiotensin System The antihypertensive effect of the angiotensin-converting enzyme (ACE) inhibitors is mediated through the renin-angiotensin system (RAS), one of many homeostatic mechanisms the body uses to regulate blood pressure. The RAS also regulates fluid, potassium, and sodium balances. The RAS is very complex, and it has other physiological effects aside from blood pressure control, but this discussion will focus on the RAS and hypertension. The effect of the RAS on blood pressure is complex, but the basic process is highlighted below. • Decreased renal blood flow, volume depletion, decrease in serum sodium, and sympathetic stimulation cause the kidneys to convert pre- renin to renin. Renin is an enzyme that converts angiotensinogen, a compound that is synthesized by the liver, to angiotensin I. • Angiotensin I (no direct biological actions and a precursor) is then changed to angiotensin II by ACE. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 5 • Angiotensin II binds to specific receptors, and it increases blood pressure by its action as a potent vasoconstrictor, increasing the secretion of the hormone aldosterone, and aldosterone increases renal tubular reabsorption of sodium and water, and stimulating the sympathetic nervous system. The net result is an increase in blood pressure, and the RAS is the primary way long-term control of blood pressure is attained. The ACE inhibitors inhibit the activity of ACE. This decreases the production of angiotensin II, increases the activity of renin, and decreases the secretion of aldosterone. The net effect is a lowered blood pressure. The RAS can also be manipulated to lower blood pressure by preventing angiotensin II from binding to the angiotensin I and angiotensin II receptors. These are G protein-coupled receptor for which angiotensin II is a ligand, and the angiotensin receptors blockers (ARBs) like valsartan prevent ligand binding to the receptor and thus diminish the vasoconstrictive action of angiotensin II. The ACE inhibitors and the ARBs both lower blood pressure by their effects on the RAS by but different methods. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 6 Pharmacological Profile Of Ace Inhibitors Angiotensin-converting enzyme inhibitors are available as tablets and a solution for injection. ACE inhibitors are also available combined with a thiazide diuretic or with a calcium channel blocker. The ACE inhibitors currently available in the United States are listed in Table 1. The generic name is followed by the trade name. Table 1: ACE Inhibitors Benazepril (Lotensin) Captopril (Capoten) Enalapril (Vasotec) Fosinopril (Monopril) Lisinopril (Prinivil, Zestril) Moexipril (Univasc) Perindopril (Aceon) Quinapril (Accupril) Ramipril (Altace) Trandolapril Mavik) Pharmacological Category Angiotensin-Converting Enzyme (ACE) Inhibitor, antihypertensive. Uses There are slight differences in the prescribing information for the ACE inhibitors, but they are not significant. The four primary uses for ACE inhibitors are: 1) Treatment of hypertension, 2) Treatment of heart failure, symptomatic, reduced ejection fraction, 3) Improving left ventricular function and decreasing mortality after acute myocardial infarction, and 4) Treatment of diabetic nephropathy. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 7 US Boxed Warning Drugs that act on the RAS can cause injury, fetal toxicity, and death to a developing fetus. Discontinue an ACE inhibitor as soon as it is known the patient is pregnant. Contraindications The potential for allergic cross-reactivity between ACE inhibitors is unclear, so administration of one ACE inhibitor to patient who has had an allergic reaction to another is inadvisable. Patients With Diabetes Mellitus and Taking Renin Inhibitor Aliskiren The concomitant use of an ACE inhibitor and aliskiren in patients who have diabetes mellitus is contraindicated. Aliskiren itself has the potential to cause hyperkalemia, hypotension, and renal impairment, this risk is increased if the patient is given an ACE inhibitor,1,2 and hypotension, hyperkalemia, and renal impairment are potential adverse effects
Recommended publications
  • Angiotensin-Converting Enzyme Inhibitors Or Angiotensin II Receptor Blockers and the Risk of Developing Rheumatoid Arthritis in Antihypertensive Drug Users

    Angiotensin-Converting Enzyme Inhibitors Or Angiotensin II Receptor Blockers and the Risk of Developing Rheumatoid Arthritis in Antihypertensive Drug Users

    Jong, H.J.I. de, Vandebriel, R.J., Saldi, S.R.F., Dijk, L. van, Loveren, H. van, Cohen Tervaert, J.W., Klungel, O.H. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiology and Drug Safety: 2012, 21(8), 835-843 Postprint Version 1.0 Journal website http://dx.doi.org/10.1002/pds.3291 Pubmed link http://www.ncbi.nlm.nih.gov/pubmed/22674737 DOI 10.1002/pds.3291 This is a NIVEL certified Post Print, more info at http://www.nivel.eu Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users†‡ HILDA J. I. DE JONG1,2,3, ROB J. VANDEBRIEL1, SITI R. F. SALDI3, LISET VAN DIJK4, HENK VAN LOVEREN1,2, JAN WILLEM COHEN TERVAERT5, OLAF H. KLUNGEL3,* ABSTRACT Purpose: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are effective in the treatment of cardiovascular disease. Next to effects on hypertension and cardiac function, these drugs have anti-inflammatory and immunomodulating properties which may either facilitate or protect against the development of autoimmunity, potentially resulting in autoimmune diseases. Therefore, we determined in the current study the association between ACE inhibitor and ARB use and incident rheumatoid arthritis (RA). Methods: A matched case–control study was conducted among patients treated with antihypertensive drugs using the Netherlands Information Network of General Practice (LINH) database in 2001–2006. Cases were patients with a first-time diagnosis of RA. Each case was matched to five controls for age, sex, and index date, which was selected 1 year before the first diagnosis of RA.
  • Several Weeks Before Your Surgery, You Should Stop Taking

    Several Weeks Before Your Surgery, You Should Stop Taking

    Several weeks before your surgery, you should stop taking: All Herbal/Vitamin Supplements & Weight loss medicines One week prior to surgery, you should stop taking: Aspirin products and Anti-inflammatory products (OTC and Prescribed) Anticoagulants or blood thinners such as Coumadin, Pradaxa, Plavix, Ticlid, and Aggrenox Night before surgery: Do not drink alcoholic beverages 24 hours prior to surgery. Alcohol may increase the depth of your anesthesia or the effect of medicines you may be given. Do not smoke after midnight prior to having surgery. Smoking can cause gastric secretions that interfere with the anesthetic during surgery. You need to be fasting or nothing to eat or drink 9 hours prior to your surgery. If your surgery is before noon, nothing to eat or drink after 11pm. If your surgery is after noon, nine hours prior to surgery you may eat a light meal (toast with clear juices such as apple juice or ginger ale). Here are some other pre-surgery instructions you need to follow: Do not take the following Blood pressure medications the night before or the morning of surgery: o Do not take ACE Inhibitors : Benazepril (Lotensin), Captopril (Capoten), Enalapril (Vasotec), Fosinpril (Monopril), Lisinopril (Prinvil, Zestril), Moexipril (Univasc or Perdix), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), Trandolapril (Mavik). o Do not take ARBS (Angiotenensin II Receptor Blockers): (Atacand) Candesartan, (Avapro) Irbesartan, (Benicar) Olmesartan, (Cozaar) Losartan, (Diovan) Valsartan, (Micardis) Telmisartan, (Teveten) Eprosartan The morning of surgery when you wake, take the following medications with a small sip of water: o Parkinson’s and seizure medications, blood pressure and heart medication except as indicated above.* o Do not take your diuretics or “water pills” the morning of surgery.
  • Moexipril Hydrochloride | Medchemexpress

    Moexipril Hydrochloride | Medchemexpress

    Inhibitors Product Data Sheet Moexipril hydrochloride • Agonists Cat. No.: HY-B0378A CAS No.: 82586-52-5 Molecular Formula: C₂₇H₃₅ClN₂O₇ • Molecular Weight: 535.03 Screening Libraries Target: Angiotensin-converting Enzyme (ACE); Apoptosis Pathway: Metabolic Enzyme/Protease; Apoptosis Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 250 mg/mL (467.26 mM; Need ultrasonic) H2O : 100 mg/mL (186.91 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 1.8691 mL 9.3453 mL 18.6905 mL Stock Solutions 5 mM 0.3738 mL 1.8691 mL 3.7381 mL 10 mM 0.1869 mL 0.9345 mL 1.8691 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.89 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.89 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.89 mM); Clear solution BIOLOGICAL ACTIVITY Description Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure. Target: ACEMoexipril hydrochloride is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective [1].
  • Ideal Drug for Blood Pressure

    Ideal Drug for Blood Pressure

    Int. J. Pharm. Sci. Rev. Res., 25(2), Mar – Apr 2014; Article No. 02, Pages: 7-12 ISSN 0976 – 044X Research Article Ideal Drug for Blood Pressure D. Praba1, M. Menakha2, K.A.Jeyanthi3 1Department of Biotechnology, Thanthai Hans Roever College of arts and science, Perambalur district, Tamil Nadu, India. 2P.G. and Research Department of Botany and Microbiology, A.V.V.M. Sri Pushpam College (Autonomous), Poondi, Thanjavur district, Tamil Nadu, India. 3Department of Biochemistry, Thanthai Hans Roever College of arts and science, Perambalur district, Tamil Nadu, India. *Corresponding author’s E-mail: [email protected] Accepted on: 27-11-2013; Finalized on: 31-03-2014. ABSTRACT Blood pressure, sometimes referred to as arterial blood pressure, is the pressure exerted by circulating blood upon the walls of blood vessels. Angiotensin is a peptide hormone that causes vasoconstriction followed by increase in blood pressure. Angiotensin I is converted to angiotensin II by the enzyme angiotensin-converting enzyme (ACE). ACE is a target for inactivation by ACE inhibitor drugs. ACE inhibitors are major anti-hypertensive drugs. Here, the ACE is disease causing receptor and the ACE inhibitors used as ligand. In the present investigation, most suitable ACE inhibitor was identified from frequently prescribed drugs such as perindopril, captopril, enalapril, lisinopril, ramipril, benazepril, fosinopril, trandolapril, moexipril and telmisartan through molecular docking. Based on the precision rate of docking and e-values, Trandolapril, Ramipril and Benazepril were identified as effective drug molecules. From the present investigation it is suggested that Trandolapril, Ramipril and Benazepril drug molecules could be used for regulating the blood pressure (Hypertension).
  • Ace Inhibitors (Angiotensin-Converting Enzyme)

    Ace Inhibitors (Angiotensin-Converting Enzyme)

    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
  • Deprescribing for Older Patients

    Deprescribing for Older Patients

    CMAJ Review CME Deprescribing for older patients Christopher Frank MD, Erica Weir MD MSc See related editorial at www.cmaj.ca/lookup/doi:10.1503/cmaj.122099 and articles at www.cmaj.ca/lookup/doi:10.1503/cmaj.122012 and www.cmaj.ca/lookup/doi:10.1503/cmaj.130523 he principles that guide optimal prescribing outcomes related to medications than other older Competing interests: None for older patients1,2 (Box 1) include depre- patients. They are also more likely to have limited declared. scribing medications that are no longer indi- life expectancy than well older people of similar This article has been peer T 17 cated, appropriate or aligned with evolving goals of age. Medication lists tend to lengthen as patients reviewed. care. Deprescribing is a relatively new term that age, and there are few guidelines to inform medi- Correspondence to: focuses attention on the sometimes overlooked step cation management in the context of polyphar- Christopher Frank, frankc in medication review of stopping medications to macy, multiple morbidities and age-related @providencecare.ca improve outcomes and decrease risks associated changes to pharmacokinetics and pharmacody- CMAJ 2014. DOI:10.1503 with polypharmacy in older people.3–5 These risks namics (Box 1). All prescribers contributing to the /cmaj.131873 include nonadherence,6 adverse drug reactions,7 medication list need to be alert to “prescribing functional and cognitive decline,8 and falls.9,10 In inertia”18 (the tendency to automatically renew a Canada, more than 50% of older people living in medication even when the original indication is long-term care facilities and 27% of those living in no longer present) and should view polypharmacy the community take more than five medications a as an impetus to deprescribe when appropriate.
  • Icatibant Compared to Steroids and Antihistamines for ACE-Inhibitor-Induced Angioedema

    Icatibant Compared to Steroids and Antihistamines for ACE-Inhibitor-Induced Angioedema

    KNOWLEDGE TO PRACTICE DES CONNAISSANCES ÀLA PRATIQUE CJEM Journal Club Icatibant Compared to Steroids and Antihistamines for ACE-Inhibitor-Induced Angioedema Reviewed by: Tudor Botnaru, MD, CM*; Antony Robert, MD, MASc*; Salvatore Mottillo, MD, MSc* syndromes, and acute heart failure NYHA class III or Article chosen IV,aswellasthosepregnantandlactating,were Bas M, Greve J, Stelter K, et al. A Randomized Trial of excluded. Icatibant in ACE-Inhibitor-Induced Angioedema. N Engl J Med 2015;372:418-25. doi:10.1056/NEJMoa1312524. STUDY DESIGN This was an industry and government funded, multi-centre, Keywords: angioedema, icatibant, corticosteroids, ACE-inhibitor, antihistamines double-blind, double-dummy randomized phase 2 study. Block randomization was performed online. Patients were randomly assigned in a 1:1 ratio. Primary investigators and BACKGROUND patients were blinded to the treatment. Investigators who were responsible for the randomization, study-drug administration, and assessment of injection site reactions Angiotensin-converting-enzyme-inhibitor (ACEI) induced were aware of study assignments. Patients in the treatment angioedema occurs in 0.68% of those taking the group received icatibant 30 mg subcutaneously and those in medication1 and accounts for one-third of angioedema the control group (standard therapy group) received pre- cases treated in the emergency department. Upper airway dnisolone 500 mg and clemastine 2 mg (an antihistamine) compromise, potentially leading to acute laryngeal intravenously. Patients assessed the intensity of symptoms obstruction and death, may occur in up to 10% of cases.1,2 at several intervals within 48 hours. Blinded investigators Standard therapy consists of glucocorticoids and anti- further assessed the signs and symptoms. If there was no histamines.
  • Angiotensin Modulators/Calcium Channel Blocker Combinations Review 02/05/2009

    Angiotensin Modulators/Calcium Channel Blocker Combinations Review 02/05/2009

    Angiotensin Modulators/Calcium Channel Blocker Combinations Review 02/05/2009 Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to [email protected].
  • Angiotensin-Converting Enzyme (ACE) Inhibitors

    Angiotensin-Converting Enzyme (ACE) Inhibitors

    Angiotensin-Converting Enzyme (ACE) Inhibitors Summary Blood pressure reduction is similar for the ACE inhibitors class, with no clinically meaningful differences between agents. Side effects are infrequent with ACE inhibitors, and are usually mild in severity; the most commonly occurring include cough and hypotension. Captopril and lisinopril do not require hepatic conversion to active metabolites and may be preferred in patients with severe hepatic impairment. Captopril differs from other oral ACE inhibitors in its rapid onset and shorter duration of action, which requires it to be given 2-3 times per day; enalaprilat, an injectable ACE inhibitor also has a rapid onset and shorter duration of action. Pharmacology Angiotensin Converting Enzyme Inhibitors (ACE inhibitors) block the conversion of angiotensin I to angiotensin II through competitive inhibition of the angiotensin converting enzyme. Angiotensin is formed via the renin-angiotensin-aldosterone system (RAAS), an enzymatic cascade that leads to the proteolytic cleavage of angiotensin I by ACEs to angiotensin II. RAAS impacts cardiovascular, renal and adrenal functions via the regulation of systemic blood pressure and electrolyte and fluid balance. Reduction in plasma levels of angiotensin II, a potent vasoconstrictor and negative feedback mediator for renin activity, by ACE inhibitors leads to increased plasma renin activity and decreased blood pressure, vasopressin secretion, sympathetic activation and cell growth. Decreases in plasma angiotensin II levels also results in a reduction in aldosterone secretion, with a subsequent decrease in sodium and water retention.[51035][51036][50907][51037][24005] ACE is found in both the plasma and tissue, but the concentration appears to be greater in tissue (primarily vascular endothelial cells, but also present in other organs including the heart).
  • Effects of Statins on Renin–Angiotensin System

    Effects of Statins on Renin–Angiotensin System

    Journal of Cardiovascular Development and Disease Review Effects of Statins on Renin–Angiotensin System Nasim Kiaie 1,†, Armita Mahdavi Gorabi 1,†, Željko Reiner 2, Tannaz Jamialahmadi 3,4, Massimiliano Ruscica 5 and Amirhossein Sahebkar 6,7,8,9,* 1 Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran; [email protected] (N.K.); [email protected] (A.M.G.) 2 Department of Internal Diseases, School of Medicine, University Hospital Center Zagreb, Zagreb University, 10000 Zagreb, Croatia; [email protected] 3 Quchan Branch, Department of Food Science and Technology, Islamic Azad University, Quchan 9479176135, Iran; [email protected] 4 Department of Nutrition, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran 5 Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy; [email protected] 6 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran 7 Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran 8 School of Medicine, The University of Western Australia, Perth 6009, Australia 9 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran * Correspondence: [email protected] or [email protected] † Equally contributed. Abstract: Statins, a class of drugs for lowering serum LDL-cholesterol, have attracted attention because of their wide range of pleiotropic effects. An important but often neglected effect of statins is their role in the renin–angiotensin system (RAS) pathway. This pathway plays an integral role in the progression of several diseases including hypertension, heart failure, and renal disease.
  • Online Appendix

    Online Appendix

    The More We Die, The More We Sell? A Simple Test of the Home-Market Effect Online Appendix Arnaud Costinot Dave Donaldson MIT, CEPR, and NBER MIT, CEPR, and NBER Margaret Kyle Heidi Williams Mines ParisTech and CEPR MIT and NBER December 28, 2018 1 Contents A Theoretical Appendix3 A.1 Multinational Enterprises (Section III.1)..........................3 A.2 Log-Linearization (Section III.2)...............................3 A.3 Beyond Perfect Competition (Section III.3).........................6 A.3.1 Monopolistic Competition..............................6 A.3.2 Variable Markups...................................7 A.3.3 Endogenous Innovation...............................8 A.3.4 Price Regulations...................................9 A.4 Bilateral Sales (Section VI.1)................................. 12 B Empirical Appendix 12 B.1 Rich versus Poor Countries................................. 12 B.2 Additional Empirical Results................................ 13 B.3 Benchmarking IMS MIDAS data.............................. 13 B.3.1 Benchmarking to the OECD HealthStat Data................... 13 B.3.2 Benchmarking to the MEPS Data.......................... 14 B.4 ATC to GBD Mapping.................................... 15 2 A Theoretical Appendix A.1 Multinational Enterprises (Section III.1) In this appendix, we illustrate how to incorporate multinational production into our basic envi- ronment. Following Ramondo and Rodríguez-Clare(2013), suppose that each firm headquartered in country i that sells drugs targeting disease n in country j 6= i can choose the country l in which its production takes place. If l = i, then the firm exports, if l = j, it engages in horizontal FDI, and if l 6= i, j, it engages in platform FDI. Like in Ramondo and Rodríguez-Clare(2013), we assume that firm-level production functions exhibit constant returns to scale, but we further allow for external economies of scale at the level of the headquarter country for each disease.
  • Angiotensin–Aldosterone System Fingerprint in Patients with Primary

    Angiotensin–Aldosterone System Fingerprint in Patients with Primary

    1 181 P Wolf and others RAAS activity in adrenal 181:1 39–44 Clinical Study insufficiency Identifying a disease-specific renin– angiotensin–aldosterone system fingerprint in patients with primary adrenal insufficiency Peter Wolf1, Johanna Mayr1, Hannes Beiglböck1, Paul Fellinger1, Yvonne Winhofer1, Marko Poglitsch2, Alois Gessl1, Alexandra Kautzky-Willer1, Anton Luger1 and Correspondence should be addressed Michael Krebs1 to M Krebs 1Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna and Email 2Attoquant Diagnostics, Vienna, Austria michael.krebs@meduniwien. ac.at Abstract Background: In patients suffering from primary adrenal insufficiency (AI) mortality is increased despite adequate glucocorticoid (GC) and mineralocorticoid (MC) replacement therapy, mainly due to an increased cardiovascular risk. Since activation of the renin–angiotensin–aldosterone system (RAAS) plays an important role in the modulation of cardiovascular risk factors, we performed in-depth characterization of the RAAS activity. Methods: Eight patients with primary AI (female = 5; age: 56 ± 21 years; BMI: 22.8 ± 2 kg/m2; mean blood pressure: 140/83 mmHg; hydrocortisone dose: 21.9 ± 5 mg/day; fludrocortisone dose: 0.061 ± 0.03 mg/day) and eight matched healthy volunteers (female = 5; age: 52 ± 21 years; BMI: 25.2 ± 4 kg/m2; mean blood pressure:135/84 mmHg) were included in a cross-sectional case–control study. Angiotensin metabolite profiles (RAS-fingerprints) were performed by liquid chromatography mass spectrometry. Results: In patients suffering from primary AI, RAAS activity was highly increased with elevated concentrations of renin concentration (P = 0.027), angiotensin (Ang) I (P = 0.022), Ang II (P = 0.032), Ang 1-7 and Ang 1-5.